H1 2021 I : ALBPS – Nasdaq: BPTS Forward Looking Statements

All statements pertaining to future financial and/or operating results, future growth in research, clinical development, and potential opportunities for Biophytis SA (the “Company”) and its products, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and other risks discussed in the Company’s registration statement on Form F-1 and other reports filed with the Securities and Exchange Commission (the “SEC”), which are available for review at http://www.sec.gov/. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to publicly update or review such statements to reflect events or circumstances after the date of this presentation, except as required by law.

2 Corporate Highlights

HQ location: Paris, Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes Founded: 2006 associated with aging and improving functional outcomes for patients suffering from age-related diseases. Our small molecules are aimed at stimulating biological resilience and are developed through a drug discovery platform based on a reverse Employees: 30 pharmacology approach. Euronext growth (ALBPS) : July 2015 Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment of mobility disability in elderly patients with Nasdaq (BPTS): February 2021 sarcopenia in a Phase 2 clinical study (SARA) in the United States and Europe. It is also being studied for the treatment of severe respiratory manifestations in COVID- 19 in a Phase 2-3 clinical study (COVA) in Europe, Brazil, and the US. A pediatric Market cap: €117M (May 11, 2021) formulation of Sarconeos (BIO101) is being developed with IND granted (MYODA) for the treatment of Duchenne Muscular Dystrophy (DMD). Cash: €18.8 M as of December 31, 2020

Key partner: Sorbonne University

3 Executive team

Samuel Agus - CMO Stanislas Veillet - Founder & CEO • MD, PhD, Board-certified • PhD in genetics, AgroParisTech Neurologist • 25+ years in biotech; Pharmacia- • 15+ years pharma/biotech Monsanto, Danone Group experience including Abbott, Shire and Teva Pharmaceuticals

Pierre Dilda - CSO Waly Dioh - COO • PhD in pharmacology (Paris V) • PhD in phytopathology (Paris XI) • 25 years experience in and MBA pharmaceutical research, in both • 21+ years biotech experience in academic and industrial settings France and the U.S. and R&D at Monsanto Evelyne Nguyen- CFO • 30+ years of experience in Corporate Finance for International Pharma & Biotech companies (BMS, LFB, Nicox SA, ANMPartners) • Expertise in cross-borders transactions between Europe, US and Asia

4 Drug discovery for age-related diseases

• Sarconeos (BIO 101) Reverse pharmacology from plant natural molecule for neuromuscular and stimulating biological resilience to drug candidates respiratory diseases • Macuneos (BIO201) for eye diseases Build a Screen in Selection of proprietary cellular models best drug collection of of age related candidates • Small molecules: natural and/or natural molecules diseases and based on NCE (new chemical entity) & analogs from identification animal models • New key target against aging medicinal plant, of targets & of aging or produced under pathways genetic • Preclinical proof-of-concept & safety biotic or abiotic diseases • IP on use, process and composition stress of matter • Second generation drug candidates (BIO103, BIO203) DAPI MHC

5 Our clinical pipeline

Candidate Indication Program Preclinical Phase 1 Phase 2 Phase 3

Covid-19 COVA

Sarconeos (BIO101) Sarcopenia

DMD

Dry AMD Macuneos (BIO201) Stargardt

6 2020: A transformational year for Biophytis

Clinical Achievements Financial achievements

Launch of the new COVA study – COVID-19 • $20.1 million (€16.6 M) raise from • Part 1 first interim analysis achieved (50 patients) with positive Nasdaq IPO in Q1 2021 DMC review in Q1 2021 • Part 2 steadily progressing with 155 patients recruited in May. • €23.4 million raise in private placements The second interim analysis is expected before end Q2 2021 on Euronext in 2020 • Top line results for the full study are expected Q3 2021 • €18.8 million in cash and cash Completion of SARA-INT study recruitment – Sarcopenia equivalents as of December 31, 2020 • Phase 2: Treatment completed for the last patient in December 2020 • Top-line results expected in Q2 2021

IND Approval to start MYODA - DMD • US IND & authorization obtained • Study to start by H1 2021 depending on the evolution of the pandemic

7 Sarconeos (BIO101) activates MAS receptor, triggering key pathways for muscle metabolism, with the potential to stimulate mobility and respiratory functions

Sarconeos (BIO101) triggers two important MAS receptor downstream signaling-pathways Sarconeos in myocytes: (BIO101)

• PI3K/AKT/mTOR: Increases MAS protein synthesis Receptor • AMPK/ACC: Stimulates energy production

MAS activation in skeletal and smooth muscles stimulates muscle metabolism and strength with a potential impact on mobility or respiratory functions Protein Energy Synthesis Production AKT AMPK Pathway Pathway

8 Sarconeos (BIO101) activates the protective arm of the Renin Angiotensin System (RAS) with the potential to stimulate respiratory function in COVID-19 patients

• Sarconeos (BIO101) activates the MAS receptor, a key component of Renin SARS-CoV2 the protective arm of the Renin- (Covid-19) Angiotensin System (RAS), known for protecting muscles against catabolism, inflammation or Ace fibrosis Ace2

• The production of Ang 1-7, the Sarconeos (BIO101) natural ligand of MAS receptor, is impaired by SARS-CoV-2, which RAS RAS uses ACE2 to penetrate the lungs, classical protective causing respiratory failures arm arm

Muscle • Sarconeos (BIO101) by reactivating catabolism the RAS protective arm, has the Inflammation potential to restimulate respiratory fibrosis capacity in COVID-19 patients. senescence

9 Sarconeos (BIO101) improves muscle strength and mobility in animal models

Preservation of muscle strength Beneficial effect on mobility in immobilized mice in aged mice fed with high fat diet1

Administration of 50 mg/kg/day of Administration of 50 mg/kg/day of Sarconeos (BIO101) demonstrated a preservation of Sarconeos (BIO101) demonstrated a statistically muscle strength while immobilized (d0-d14) significant (p<0.01) improvement in maximum compared to vehicle control in hind limb- running velocity (Vmax) compared to “old” control immobilized mice mice, compensating almost completely for the loss of mobility due to aging

1. Results were presented in a poster at the SCWD conference in December 2016 in Berlin, Germany.

10 Sarconeos (BIO101) improves respiratory functions in animal models

Improves lungs Improves respiratory function mechanical (Plethysmography) properties (Flexivent)

Chronic (8 week) daily administration of C57BL10-mdx mice treated with 50 50 mg/kg/day of Sarconeos (BIO101) mg/kg/day of Sarconeos (BIO101) over 8 statistically significantly (p<0.001) weeks showed an improvement in airway improved lungs mechanical properties responsiveness (PenH) as compared to measured by airway resistance untreated control C57BL10-mdx mice

Results were presented in October 2019 during the WMS conference in Copenhagen with posters, and in March 2019 at the annual international congress of Myology in Bordeaux, France

11 Sarconeos (BIO101) results in Phase 1 study (SARA-PK)

ELDERLY HEALTHY VOLUNTEERS

Sarconeos (BIO101) showed a dose dependent effect on biomarkers of muscle growth and repair (PIIINP) and a dose dependent negative effect on muscle wasting (myoglobin)

Single and multiple ascending doses tested in 54 healthy adult and elderly (over 65 years) volunteers

Safety profile: No Severe Adverse Events

Two active doses (175 & 350 mg b.i.d.) have been selected for the upcoming Phase 2 studies

12 COVA Study: targeting hospitalized patients with respiratory failure, and not intubated Targeted populations

Severe cases: signs of respiratory Critical cases: de-compensation, not Patients aged 45 and above, with proven COVID-19, requiring requiring ventilation and severe respiratory symptoms: mechanical • With evidence of respiratory decompensation ventilation ≤7 days before start of study medication, meeting one 5% 45+ of the following: 14% • Tachypnea: ≥ 25 breaths per minute • Arterial oxygen saturation ≤92%

81%

Allowed medications: Adapted from Wu et al. • Antiviral agents such as Remdesivir, Bamlanivimab, JAMA, 2020 • Anti- inflammatory agents such as Dexamethasone Mild cases: infection without or with mild signs of pneumonia

13 The COVA study in COVID-19 is now in Phase 3

• iDMC recommended the Design Endpoints Patient Population continuation into part 2 recruitment during Q1 • A Phase 2-3 seamless study design • Part 1 (N=50): First interim • Age: 45 years old or over 2021 based on the analysis • Global, multi-center, analysis; Obtain safety and • Hospitalized for severe of the first 50 patients double-blind, placebo- tolerability data on Sarconeos respiratory symptoms and with controlled group sequential (BIO101) proven Covid-19 infection • More than 155 patients (2 parts), adaptive design • Part 2 (N=155): 2nd interim enrolled as of May 2021 in • Patients with respiratory failure • International study including: analysis; promising zone analysis not yet requiring mechanical 34 clinical centers US, Brazil, France & Belgium and confirm or reassess sample size ventilation • Second interim analysis • iDMC is monitoring the safety • Final analysis Q3 2021 (N= 310 up • Oxygen saturation less than 92% (155 patients) expected and efficacy of the treatment to 465): Confirmation of the effect of Sarconeos (BIO101) in in Q2 2021 by running two interim analyses preventing further respiratory • Topline results expected deterioration in Q3 2021

Product 2020 2021 350 mg b.i.d of Sarconeos COVA (BIO101) Phase 2-3

*Independent Data Monitoring Committee

14 Sarcopenia: a large unmet medical need

NO CURRENTLY APPROVED DRUGS • Age-related degeneration of skeletal muscle characterized by a loss of muscle mass, strength and functional issues such as the ability to stand and/or walk

• A major cause of mobility disability, resulting in a loss of independence and increased risk of adverse events (for example falls), which can shorten life expectancy

Sarconeos (BIO101): Only drug candidate in Phase 2 currently being tested for sarcopenia Myostatin inhibitors halted for lack of effectiveness in neuromuscular diseases

• Prevalence estimated between 6-22% in the elderly (defined as over 60 years of age), a population expected to double from approximately 962 million in 2017 to 2.1 billion by 20501

1United Nations’ World Population Prospects: 2017 Revision

15 The SARA-INT Phase 2 sarcopenia trial is nearing completion

• Last patient out in Design Endpoints Patient Population December 2020: 196 participants completed • Global, double-blind, randomized, Primary • Age: 65 years old or over the study over 233 placebo-controlled trial: • 400-meter walk test (400MWT) - • Low mobility measured by Short patients initially enrolled NCT03452488 0.05 m/s is considered the minimal Performance Physical Battery with sarcopenia at risk • Assess safety and efficacy of two meaningful change (SPPB) ≤8 out of 12 Key secondary of mobility disability doses of Sarconeos (BIO101) • DEXA body composition as administered orally with a meal • Muscle strength (Handgrip). over 22 centers in the Patient reported outcomes (PRO measured by ALM/BMI US and Belgium over 26 weeks, as compared to (appendicular lean mass / body placebo mass index) • Topline results in • Treatment effect on improvement • Able to exercise for 30 minutes sarcopenia expected of physical function and on per day 5 days per week in Q2 2021 decrease of risk of mobility disability

Product 2019 2020 2021 175 & 350 mg b.i.d of SARA-INT Sarconeos (BIO101) Phase 2

*Independent Data Monitoring Committee

16 DMD: No cure and limited treatment options

Proportion of ambulatory class in DMD1 Rare, genetic neuromuscular disease in male children characterized by accelerated degeneration of muscles, responsible for loss of mobility, respiratory failure and 100% cardiomyopathy, leading to premature death. 90% 80% 70% 60% No known cure and limited treatment options, including corticosteroids and targeted therapies (exon-skipping in U.S. 50% & stop codon in EU) that treat approximately 13% of DMD 40% patients with specific genetic mutations. 30% 20% 10% 0% US (n=284) Germany Italy UK (n=191) We received orphan drug designation (ODD) in 2018 from (n=173) (n=122) the FDA and EMA for Sarconeos (BIO101) in DMD. Ventilation support Late nonambulatory (age 16 or older) Early nonambulatory (age 12–15) Late ambulatory (age 8–11) Early ambulatory (age 5–7)

1. Source: Landfeldt et al., Neurology, 2014. 17 MYODA plans to start Phase 1-2-3 clinical study during H1 2021*

Design Endpoints Patient Population

• Global, double-blind, randomized, placebo- • Part 1 (N=18): Safety, tolerability & PK (initial • Age: ≥12 years old controlled trial: NCT03452488 7 days of dosing of escalating dose of • Non-ambulatory DMD patients • Assess safety and efficacy of two doses of Sarconeos BIO(101)) • Part 2 (N=48): Efficacy of Sarconeos: • Patients with respiratory failure not yet Sarconeos (BIO101) administered orally with a requiring mechanical ventilation meal over 26 weeks, as compared to placebo Respiratory function after dosing for 52 weeks • Part 3 (N= up to 200): Efficacy of Sarconeos • Treatment effect on improvement of physical BIO(101): Respiratory function after dosing for function and on decrease of risk of mobility 52 weeks disability

Product 2020 2021 2022 2023 FDA IND and CTA in MYODA Sarconeos (BIO101) Belgium granted in 2020 Phase 1-2-3 1.Independent Data Safety Monitoring Board *Timing is subject to COVID-19- pandemic and availability of financial resources

18 Dry AMD is an unmet medical need with no approved drugs

Projection of AMD prevalence in North America • AMD is a common eye disorder among people 50+ that affects (in M, mean projection)1 the central part of the retina, known as the macula 25 20 • Can impair functions such as reading, driving,10% and facial 15 recognition, and has a major impact on QoL and the ability to live 10 independently 5 0 • Multifactorial disease we believe is mainly caused by 2018 2020 2022 2024 2026 2028 2030 2032 2034 2036 2038 2040 accumulation of A2E (a byproduct of the visual pigment cycle) Early Late that leads to retinal degeneration

Projection of AMD prevalence in Europe (in M, mean projection)1 80 • 85 – 90% of AMD patients have dry AMD in some form; either early, 22% intermediate or late stage, known as geographic atrophy (GA) 60

40 • No approved treatments for any stage of dry AMD, including GA 78% 20 • We are developing Macuneos to treat patients with intermediate 0 dry AMD to prevent the development to advanced stages (wet AMD 2018 2020 2022 2024 2026 2028 2030 2032 2034 2036 2038 2040 + GA), which lead to severe vision loss Early Late

1. Source: Wang et al., Lancet Glob Health 2014; 2: e106–16. Supplemental Table 7: Projection of Number of People with Early, Late and Any AMD by Regions

19 Macuneos (BIO201) mechanism of action: Non-canonical activation of PPARs

• We believe Macuneos Anti-inflammatory potentially counteracts activity (promotes the the phototoxic effects of expression of anti- A2E by selective non- inflammatory genes) canonical activation of the trans-repressive activity of PPAR and Anti-oxidant activity PPARβ/δ in the retina (promotes the ⍺ expression of anti- • Most other PPAR ligands oxidant genes) mainly exhibit canonical activity and are associated with side Anti-apoptotic activity effects (enables pathways that prevent cell death)

20 Macuneos (BIO201) protects the retina in rodent models of dry AMD and Stargardt disease

Preservation of visual function in mice Reduced A2E accumulation in mice

Chronic oral administration of Macuneos Chronic oral administration of Macuneos decreased for 3 and 6 months increases ERG amplitude A2E accumulation by approximately 45% in Abca4-/- in ABCA4-/- RDH8-/- mice Rdh8-/- mice as compared to vehicle control mice

Results were presented in May 2016 at the ARVO conference in Seattle, WA in a poster presentation and published in PLoSONE (Fontaine et al.; 2016).

21 Key programs milestones

COVA Recruiting in Belgium, Brazil, France and US COVA Completion of Part 1 patient enrollment (50 ) in January 2021 COVA Interim analysis of Part 1 (50 patients) in Q1 2021 COVA Approvals to start Part 2 in Q1 2021 COVA Interim analysis for Part 2 (155 patients) expected in Q2 2021 COVA Completion of patient enrollment (Part 2) expected in Q2 2021 COVA Final study results (Part 1 and Part 2) expected in Q3 2021 SARA-INT Patient enrollment in the USA and Belgium completed in March 2020 SARA-INT Last patient out (LPO) completed in Dec 2020 SARA-INT Topline trial results expected in Q2 2021

22 Financials and Analyst Ratings

Support from the Financial € 18.8M Consolidated cash as of Community December 31, 2020 • Kepler Chevreux: Pierre Alexandre Désir vs • Invest Securities: Jamina El Bougrini • HC Wainwright: Yi Chen, Ph.D., CFA 12M€ vs December 31, 2019

23 Intellectual Property portfolio – Neuromuscular & respiratory diseases

• We hold exclusive commercial rights through licenses of each of our drug Neuromuscular and respiratory diseases candidates. 10 families of patents covering production • IP is jointly owned with Sorbonne University & sometimes with other process, second generation compounds and academic research institutions1. various applications such as sarcopenia, • Patent portfolio covers 10 patent families, including a total of 24 co-owned myopathies (DMD), disuse atrophy, spinal issued patents and a total of 26 co-owned patent applications. muscular atrophy, respiratory function and • Issued patents: 5 European, 2 U.S., and 17 in ROW, including China, Japan. COVID-19 • Pending applications: 2 European, 5 U.S., and 19 in ROW, including China, Japan, South Korea

24 co-owned issued patents 26 co-owned patent applications

24 Intellectual Property portfolio – Retinal Diseases

• We hold exclusive commercial rights through licenses of each of our drug Retinal diseases candidates. 5 families of patents covering 2 classes of • IP is jointly owned with Sorbonne University & sometimes with other compounds and their applications for dry academic research institutions. age-related macular degeneration (AMD) • Patent portfolio covers 5 patent families, including a total of 16 co-owned and Stargardt disease issued patents and a total of 10 co-owned patent applications. • Issued patents: 4 European, 3 U.S., and 9 in ROW, including China, Japan. • Pending applications: 10 in ROW, including China, Japan, South Korea.

16 co-owned issued patents 10 co-owned patent applications

25 2021 Outlook

* Timing is subject to The COVA study COVID-19- pandemic • Final study results (Part 1 and Part 2) expected in Q3 2021. and availability of • Assuming positive data, subject to any COVID-19 related delays, the Company anticipates applying for EUA in the US financial resources and conditional market approvals in EU in Q3 2021. • Assuming authorizations for the above applications, marketing preparation could start around the end of 2021.*

The SARA -INT study • Following the last visit of the last patient in December 2020, top-line results of the Phase 2 trial are expected during Q2 2021. • Depending on Phase 2 results a Phase 3 study could be commenced in 2022.*

The MYODA study • Subject to any COVID-19 related delays, the Company intends to start the Phase 1-2-3 MYODA trial in H1 2021.*

26 Scientific advisory board

Pr. Jean Mariani Dr. Roger Fielding • Professor of neuroscience and biology of aging • Professor of Medicine, Tufts University School and Director of Charles Foix Institute of Longevity of Medicine at Sorbonne University • Director and Sr. Scientist Jean Mayer USDA • Emeritus Professor (PU-PH) at the Sorbonne Human Nutrition Research Center on Aging University’s School of Medicine

René Lafont Dr. Thomas Voit • Co-Founder & Professor emeritus and • Professor, University College London former Dean of the life sciences • Director of the Research Centre of the Great department at Sorbonne University Ormond Street Hospital for Children • 185 scientific articles + 59 reviews and book chapters

Pr. Jose-Alain Sahel Dimitri Batsis • Chair of the department of ophthalmology at • Associate Professor Harvard Medical School, University of Pittsburgh School of Medicine and Massachusetts Eye and Ear director of the UPMC eye center • Co-Director of the Harvard Medical School • Founder and director of the Vision Institute in Department of Ophthalmology AMD Center Paris and professor at the Sorbonne’s medical of Excellence; Associate Scientist, school Massachusetts Eye and Ear

27 Board of directors

Pr. Jean Mariani Stanislas Veillet - Founder & CEO • Professor of neuroscience and biology of • PhD in genetics, AgroParisTech aging and Director of Charles Foix Institute • 25+ years in biotech; of Longevity at Sorbonne University Pharmacia-Monsanto, Danone • Emeritus Professor (PU-PH) at the Group Sorbonne University’s School of Medicine

Jean M. Franchi Dimitri Batsis • Independent Director • Independent Director • 20+ years leading financial • Entrepreneur, Founder of Zeni teams in public and private Corporation, Drone Volt pharmaceutical, biotech, and • 20 years in the High-Tech sector diagnostics sectors Nadine Coulm • Independent Director • 20 years of experience as CFO in charge of IR & Financing with Korian, , Darty Danone & Casino

28 Appendix

29 From a Sorbonne University spin-off to a successful clinical-stage biotechnology company: 100M€ raised to date

• Initiated SARA-INT Phase 2 • IPO on Alternext Paris that clinical trial raised €10.0 M • Incorporated on Sept 26, 2006 • Received orphan drug • Opened U.S. subsidiary in designation for Sarconeos • First patents filed in 2007 • Launch of COVA project with Cambridge, MA (BIO101) in DMD in US and Sarconeos (BIO101) in COVID-19, • Raised €800 K with Seventure • Raised €6.0M in private Europe started in US, Europe and Brazil Partners placement • Raised €10M in notes • 30M€ raised in new equity

2006 – 2008 2009 – 2012 2015 2016 – 2017 2018 2019 2020 2021

• 2009 €2.2 M Round A with VC’s • 2016 initiated and completed SARA- • Set up €24M • IPO on Nasdaq • 2009 launched first human clinical PK Phase 1 clinical trial bond financing February 2021: trials for Sarconeos (BIO101) • 2017 raised €18.0 M in private • Filed and 16M€ raised • 2012 €3.0 M Round B with VC’s placements granted IND for • Set up €15M bond financing Sarconeos • Initiated SARA-OBS clinical trial (BIO101) in DMD

30 THANK YOU

Contacts:

Stanislas Veillet – CEO [email protected]

Evelyne Nguyen – CFO [email protected]

Investor relations: [email protected] www.biophytis.com